The Index
400 dossiers · 1 need attention
A research screener for every company we cover. Search a name or ticker, then sort and triage dossiers by coverage freshness, our conviction and trading relevance.
No call62 names· avg TR 7 | ||||||||
| A genuine engineering bet (tendon-driven safe humanoid + in-home data flywheel) wrapped in a marketing fiction — NEO ships "autonomous" but runs on stranger-in-a-VR-headset teleop, and the company most likely to make it work, OpenAI, just became its competitor. | — | 0 | ||||||
| The only humanoid actually billing paying customers for real warehouse work — but it is being squeezed between Figure's $39B AI-narrative capital and Unitree's $16K Chinese hardware, and SoftBank already tried to buy the whole thing for under $1B. | — | 8 | ||||||
| The best-funded biotech ever, reorganizing toward AI after four years and zero disclosed clinical assets — a platform bet whose lead rivals just beat it into the clinic; WATCHING, not ownable, until a named program and a runway figure exist. | — | 8 | ||||||
| The credible enzymatic-DNA-synthesis survivor — a real fidelity moat (1,005-base record, 50 kb clonal, ~99.9% stepwise yield) now distributed through Danaher/IDT — but it is a sub-$25M-revenue tools shop selling a faster picks-and-shovels commodity into a brutal synbio funding winter; WATCHING as a private until an IPO path or an IDT buyout crystallizes the value. | — | 8 | ||||||
| The best business in AI on every metric that isn't valuation — enterprise-led, multi-cloud, ~$30B+ run-rate doubling on weeks — wrapped in a ~$965B mark that already prices a decade of flawless execution and rests on a circular ring of vendor-investors funding ~$180B of compute the company hasn't yet earned the margins to pay for. WATCHING, bull on the business / bear on the entry price. | — | 0 | ||||||
| The credible #2 Western humanoid — NASA-pedigree hardware + Google DeepMind's brain + the Mercedes/GXO/Jabil go-to-market — but priced for a labor-replacement future it has not yet shipped, into a market where Unitree is collapsing the price floor from below. | — | 8 | ||||||
| The softest neural interface on the planet with zero chronic human data — a genuine materials-science lead wrapped around an unproven clinical thesis and a behind-the-pack regulatory position; a WATCH, not a bet, until a Fleuron probe records cleanly past 90 days in a living brain. | — | 8 | ||||||
| The purest public-market-bound bet on optical I/O — strategically anchored by Nvidia + AMD + TSMC, but priced at $3.75B into a thesis (third-party CPO chiplets inside the GPU package) that its own anchor investors are simultaneously building in-house. | — | 8 | ||||||
| The only AI-bio company building a proprietary, legally-clean training dataset 100x deeper than UniProt — own the data layer of TechBio and it is a generational compounder; if foundation labs (ESM, AlphaFold) reach "good enough" on public data first, it is a beautifully-sourced commodity. Watch for an EDEN-derived therapeutic deal with real economics and a priced Series C. | — | 8 | ||||||
| A real lab-in-the-loop antibody-engineering shop with blue-chip pharma validation (AbbVie/Lilly/Merck/Amgen) and now its own clinic-bound ADC — but it is dramatically out-capitalized ($145M vs. $1B+ peers) and is becoming a Lilly satellite; WATCHING as a private, with the IND-into-clinic 2026 prints as the only catalyst that re-rates it. | — | 8 | ||||||
| The most-implanted BCI on Earth and the worst-capitalized relative to its peers — a 2008-era electrode bet now owned by a stablecoin issuer, where the moat is two decades of human data and the kill-switch is glial scar tissue. Watching, not buying, until a De Novo/PMA submission and a clean secondary mark say the Tether money actually bought commercialization rather than just runway. | — | 0 | ||||||
| A real #2 to SpaceX with anchor demand and a flight-proven heavy lifter — but a single-pad, single-stage company that just lost its only launch site and its only customer's confidence in the same month, forced into its first outside raise at the exact moment SpaceX vacuums up the capital. | — | 8 | ||||||
| The only at-scale, FDA-cleared, revenue-bearing non-invasive BCI franchise heading to a public listing — but it is a Chinese military-civil-fusion controversy with a confidential HK IPO, no public financials, and a US national-security cloud, so it is un-investable on a US/UK book until it trades and discloses. | — | 8 | ||||||
| Alphabet's $2.5B/12-year longevity moonshot just lost its only pharma partner — AbbVie walked after the lead asset flopped — and the surviving thesis is now a 3-asset rare-disease biotech (ADPKD antibody the crown jewel) wearing an aging-research halo; not a 2026 tradeable, watch the ADPKD Phase 2 readout as the sole de-risking event. | — | 8 | ||||||
| The clear commercial leader in laser weeding with a real data flywheel and a fresh CFO-led pre-IPO posture — but penned into the narrow, cyclical specialty-crop niche with a ~$370M-marked-up-to-~$550M valuation that already prices the broadacre dream it has not yet earned. WATCHING, not buying, until the AutoTractor RaaS line and a credible row-crop path prove the TAM is bigger than vegetables. | — | 8 | ||||||
| The single most exciting private name in AI-bio — Chai-2/3 is the first AI antibody platform with a wet-lab-validated, repeatedly-improving hit rate AND signed pharma revenue (Lilly + Pfizer); the bet is whether a portable, lab-light software platform can defend value capture against Isomorphic's deeper engine and the platform-vs-asset value trap. WATCHING for an IPO that is 2-3 years away. | — | 8 | ||||||
| A non-invasive, AR-first AAC headset with a real FDA-Breakthrough wedge and two distribution partners — but at a ~$25–46M valuation after 12 years and ~$25–32M raised, it is a mission-driven research-tools / assistive-device niche player, not a venture-scale BCI bet; the asymmetry is acquisition-by-a-giant, not an IPO. | — | 8 | ||||||
| The only European bidirectional-BCI in US human trials, backed by the BioNTech family office (Santo/Strüngmann) — a Breakthrough-Device, stroke-rehab-first asset that is structurally early and structurally under-capitalised; WATCHING for the funding round that proves the Strüngmanns will write a BioNTech-scale cheque, not just an option. | — | 8 | ||||||
| The cleanest pure-SaaS bet in AI protein engineering — Google-pedigreed, wet-lab-backed, already billing 6 of the top-25 pharma — but it has deliberately disarmed itself of the one thing that creates equity value in this field (it owns no molecule, takes no royalty, signs no IP), so it is selling a fast-commoditizing copilot whose best customers (Novo Nordisk) are simultaneously funding the open-source models that erode its moat. | — | 8 | ||||||
| The lab that broke the cost-of-intelligence narrative and now anchors China's sovereign AI stack — a frontier-class open-weight model trailing the closed leaders by 3-6 months at ~1/50th the unit cost, but state-captured, un-investable to US capital, and monetizing almost none of the value it creates. | — | 0 | ||||||
| The most-cited consumer-EEG brand in research, now repricing itself as "cognitive AI infrastructure" — but 23 years in, ~$10M ever raised, and a Chilean supreme-court delete order make it the BCI category's pioneer that capital forgot, not its winner. WATCHING — a be-early IPO-readiness name, not yet investable. | — | 8 | ||||||
| A real ag-distribution disruptor that just admitted the hard part — the Oct-2025 GCS spin-off makes FBN an asset-light marketplace whose thesis now lives or dies on take-rate and lending, not on owning crop-protection inventory; an eventual IPO is a story, not a date, and the entry round you'd actually clear is a flat-to-down one. | — | 8 | ||||||
| The category's pace-setter and best-funded vertically-integrated humanoid bet — but the $39B mark prices a fleet that, on the public record, is still a pilot; WATCHING for the BMW-pilot-to-multi-customer-scale proof that converts the story into a tradeable S-1. | — | 1 | ||||||
| Forest is a nonprofit research instrument, NOT an equity — the tradeable BCI bet it incubated walked out the door as Merge Labs (Altman/OpenAI, $850M); track Forest as the science-de-risking front-end, position via Merge or Butterfly (BFLY), never Forest itself. | — | 8 | ||||||
| The cheapest electron-storage on the grid at the worst round-trip efficiency on the grid — a genuine multi-day monopoly whose moat (iron at $0.10/kWh, a US steel-mill factory, ArcelorMittal upstream) is only worth owning if regulators keep paying for firm capacity rather than cheap throughput; the Google $1B deal proves demand exists, the sub-40% RTE proves the bet is on policy and capacity value, not arbitrage. | — | 0 | ||||||
G | The single-partner-concentration bear point is dead — Gero now has TWO pharma validations, and the bigger one (Chugai/Roche, exclusive worldwide antibody rights, up to ~$250M milestones + royalties) is disclosed on a listed Roche subsidiary's own corporate filing, the most credible source in this dossier. Plus an open-sourced sequence-to-molecule model (ProtoBind-Diff). Still WATCHING (private, no public security, no named owned IND asset), but the watch is materially higher-quality — conviction on the platform-validation leg rises from "one partner, unfalsifiable" to "two top-tier pharma partners + a verifiable open-source artifact." The asymmetric event is now a partner advancing a target to the clinic or an institutional/crossover up-round. | — | ||||||
G | The crown jewels and the brain already left for Nvidia for ~$17–20B; what remains is a cash-rich but architecturally-cornered inference cloud whose flagship Saudi demand evaporated — a melting-ice-cube neocloud, not the LPU disruptor the headlines sold. | — | 8 | |||||
| The profitable, un-hyped grandfather of non-invasive BCI — a 27-year Austrian bootstrap that quietly owns the research-EEG install base and is turning recoveriX neurorehab into a franchise annuity; a real cash-flowing business but NOT a tradeable IPO candidate (no venture capital, ~$24M est. value, founder-owned), so it is a WATCH-the-category tell, not a position. | — | 8 | ||||||
| The best modulator in AI optics — but a modulator-only company in a market where the indium-phosphide laser, not the modulator, is the scarce asset; the $80M Series C buys it a foundry-scale shot at owning the TFLN layer before silicon-photonics incumbents fold thin-film into their vertically integrated stacks. | — | 8 | ||||||
| A George Church / Flagship gene-editing platform whose entire "freedom-to-operate" moat — edit a rival's already-GM trait and call it your own — is precisely what Corteva is suing to invalidate; a Jan-2026 ~33% site layoff one year after a "robust" $144M raise says the commercialization clock is running faster than the cash. | — | 8 | ||||||
| The best-positioned European BCI pure-play and the only graphene-native one — but it is a Series-B, pre-revenue spin-off two full funding rounds behind Neuralink/Precision, and its material moat is unproven precisely where its closest competitor (Precision's Layer 7) already has FDA clearance; a watch-and-wait private, not yet investable, gated on a Series C + a graphene-specific regulatory de-risking event. | — | 8 | ||||||
| The cautionary tale of the agtech bubble — a $3.5B "biology-will-rewire-farming" thesis that survived only by shrinking into a soil-carbon broker; the equity is impaired by ~94% and the surviving business is a thin-margin MRV middleman in a market with an additionality problem. WATCHING, not buyable — and not investable until there is a real revenue/margin disclosure, not a credit-tonnage press release. | — | 8 | ||||||
| A genuinely good optical-imaging instrument company wearing three failed business models — capital-starved ($158M total, no priced round since Dec-2023) and IPO-irrelevant while the rest of BCI raises billions; WATCHING, not investable, until a real revenue line or a strategic acquirer appears. | — | 8 | ||||||
| The first company to put epigenetic age-reversal into a human body — a binary, single-asset bet where a clean Phase 1 safety read on OSK reprogramming is worth more than the whole longevity field's $4B+ of pre-clinical promises, and a single inflammation or tumor signal ends it. | — | 8 | ||||||
| World's first listed pure-play photonic-computing stock — and a ~640x-sales SOE-backed China name with $15M revenue, a $185M annual loss and Huawei owning 98% of its market; the technology is real, the equity is a momentum trade priced for a future that is 5 years out. | — | 0 | ||||||
| The purest public-markets-bound bet on AI's copper wall — but it is racing NVIDIA, Broadcom and TSMC to commercial CPO from outside the package, and "2027 volume shipments" means the $4.4B mark is paid entirely on a roadmap. | — | 8 | ||||||
| The first company poised to win an FDA label for "lifespan extension" in any species — a genuinely novel regulatory beachhead on a large, growing owner-pays pet-pharma market — but the bet rides on one not-yet-read-out 1,300-dog trial, a surrogate-style ("reasonable expectation") approval, and a single CMC section still outstanding; WATCHING (privately ownable conviction, no tradeable instrument) with the STAY lifespan readout as the binary. | — | 8 | ||||||
| Europe's only credible frontier lab — a sovereignty-and-infrastructure bet, not a model-quality bet; the moat is regulatory/political, the risk is that "good enough, in Europe, on-prem" gets out-priced by Chinese open weights before the €20B mark is earned. | — | 8 | ||||||
| A dead company — Zimeno/Monarch shipped 500 real tractors but never a real business; collapsed into an assignment-for-creditors and an IP-only Caterpillar acqui-hire. Uninvestable; value here is the post-mortem, not a position. | — | 8 | ||||||
| A blueberry-sized, battery-free epidural stimulator with a Medtronic-grade team and a clean FDA IDE — but it is a single-asset, sub-$30M minnow in a field of nine-figure whales, and its closest peer (Inner Cosmos) already has the clinical lead. | — | 0 | ||||||
| The category's brand and bandwidth leader, but the bet is binary on durable signal-at-scale and CMS reimbursement — not yet a tradeable security, and the moment a Synchron or Precision reaches a pivotal trial first, Neuralink's "lead" is narrative, not regulatory. | — | 8 | ||||||
| A platform-quality data moat (1,000× the field's reprogramming-screen data) wrapped around an unproven biology, priced at $3.1B pre-IND for a 2027 first-in-human — the bet is the engine, not the liver drug, and the engine won't be falsifiable for 24+ months while a rival is already in the clinic. | — | 8 | ||||||
| The revenue leader that turned into the cash-burn leader — a $1.4T compute book financed against a P&L losing ~$14B a year, where the only question that matters is whether the IPO window opens before the funding treadmill stalls. | — | 8 | ||||||
| A genuinely differentiated all-optical scale-up fabric with a real CEO and a real AMD/ARIA anchor — but a $93.5M micro-cap fighting $1.2B–$4.4B peers and a hyperscaler-backed open-standard tide; the bet is a strategic acqui-buy (à la Marvell/Celestial), not a standalone IPO. | — | 8 | ||||||
| The highest-bandwidth intracortical BCI just put its wireless device in a human brain (17 Jun 2026) — but it is two patients into an EFS, ~3-5 years from revenue, and out-capitalized ~3-4:1 by Neuralink, so the bet is "bandwidth wins the speech-prosthesis category" against a far better-funded field. | — | 8 | ||||||
| The strongest research bench in robot learning, priced like a product company while still being a research project — own the index (NVIDIA/data), not this single ticket, until a paying-fleet number or a π1 zero-shot result exists. | — | 8 | ||||||
| The category-defining gene-edited nitrogen-fixation company with real revenue (>$100M, 2023) and a tier-1 syndicate — but the product only displaces 15-30% of synthetic N, independent university trials largely fail to find a yield benefit, and it has not raised primary capital since its July-2021 $430M / $2B Series D; WATCHING a private name living off a five-year-old round whose terminal value hinges on an unresolved efficacy question. | — | 8 | ||||||
| The only FDA-cleared, commercially-shipping cortical BCI — but it is selling a 30-day surgical-monitoring tool, not the chronic implant the $500M valuation is priced on; Medtronic is the real tell, IP overhang from Rapoport's Neuralink past is the real risk. | — | 8 | ||||||
| The best-capitalised, hardest-physics bet in quantum — $4B+ in private + sovereign money betting that silicon-photonic fusion-based computing leapfrogs straight to a million error-corrected qubits by ~2027, with the one fact that matters still unproven (a utility-scale machine running) and a freshly installed operator-CEO signalling the company is now an execution problem, not a science one. | — | 8 | ||||||
| The most credible analog-photonic-compute bet in Europe — a vertically-integrated TFLN coprocessor with a real fab, a first paying cloud customer (IONOS) and an ARM-founder-grade board — but at $80M raised it is a seed-stage David swinging at a $4B-valued field (Lightmatter) and a just-acquired peer (Celestial AI → Marvell, $5.5B); WATCHING for IPO-proximity, not yet tradeable. | — | 8 | ||||||
| The best-engineered way to lose to PsiQuantum — a genuine deterministic-single-photon moat and real machine sales, capitalized at ~1% of its photonic rivals; a sovereign-Europe call option, not a standalone winner. | — | 8 | ||||||
| A billionaire-seeded Swiss "hallmarks-of-aging" holdco that quietly went dark — rebranded to Centenara in Sep-2024, lead eye asset terminated, holdco comms silent ~21 months; the ONLY live value driver is a separately-financed Belgian portco (Rejuvenate Biomed RJx-01, Ph2 COPD-sarcopenia, topline end-2026). Un-investable as a private until an IPO path or a single de-risked asset emerges; WATCHING the RJx-01 readout only. | — | 8 | ||||||
| No longer a rocket startup — an Eric Schmidt-controlled option on Terran R becoming the launch arm of an orbital-AI-datacenter thesis, gated entirely on an unflown late-2026 maiden flight and carrying a stale $4.2B (2021) mark that almost certainly no longer holds. | — | 8 | ||||||
| A genuine builder's longevity platform de-risking faster than its peers, but the $1.8B mark is a 64% haircut off the $5B it was chasing six months ago — own it only after the August RTR242 readout converts "no tox" into a real biomarker signal, not before. | — | 8 | ||||||
| A credible Oxford/Münster silicon-photonics team that pivoted from a losing optical-compute bet to the right one — all-optical circuit switching — and shipped a real 32-port product, but it is a ~£137M-valued, sub-$50M-raised minnow standing in a lane Nvidia, Lumentum and a $4.4B Lightmatter are all paving; WATCHING, not investable, until a named hyperscaler design win proves the silicon-photonic-OCS approach beats incumbent MEMS in production. | — | 8 | ||||||
| World-class robotic hands and the #3 humanoid patent estate on Earth, attached to a balance sheet that already had to sell its best asset (the Apptronik stake) to make payroll — this is an IP carcass walking, far likelier to be acqui-hired or stripped for patents than to IPO independently. | — | 8 | ||||||
| The leading robot-foundation-model pure-play by capital and strategic syndicate, but its $14B mark prices a software-layer monopoly that the Foxconn/Blackwell line has yet to prove and that Physical Intelligence + NVIDIA's own GR00T are both armed to contest. | — | 8 | ||||||
| A structurally sub-scale #6 battery maker whose survival now rests on a US-policy bet that just inverted — the Ford anchor is gone, EV demand cratered, and the entire growth pivot (ESS/LFP) is a margin-thin race into China's home turf; only the SK Group balance sheet keeps it solvent, and there is no tradeable security to express a view on. | — | 8 | ||||||
| The only credible bet on FULL (both-stages) reuse besides SpaceX — a metallurgy/physics moat the others ducked — but it is a single-vehicle, zero-revenue, zero-flights company whose entire value is gated on one un-flown second stage surviving reentry; WATCHING, not investable, until Nova reaches orbit and the upper stage comes home intact. | — | 8 | ||||||
| The safest, most surgically scalable path into the brain and the only BCI Apple made a native input — but it bet the company on "good enough" 16-electrode bandwidth, and its own third-gen "whole-brain" pivot is a confession that the moat it is famous for may be the ceiling it has to escape. | — | 8 | ||||||
| The only profitable humanoid maker and #1 by volume — but the float is a Shanghai-only embodied-AI bet whose revenue is 74% lab demos, not labor replacement, and whose Western TAM is being legislated to zero. | — | 8 | ||||||
X | A frontier lab fused into Musk's compute-and-distribution empire — Grok is a fast-following #4 model bankrolled by a $30B/yr capex furnace; the real instrument is now SpaceX equity at a $1.25T mark, not a standalone xAI bet. | — | 8 | |||||